Quick Summary
This study looked at tryptophan, a building block the body uses to make serotonin (a chemical linked to mood and energy). Researchers compared blood tryptophan levels in 23 people with ME/CFS and 42 healthy people. They found that ME/CFS patients had higher levels of free tryptophan available to the brain, but the patients were not all the same—some had normal serotonin levels while others had elevated levels.
Why It Matters
Serotonin dysfunction has long been hypothesized in ME/CFS, and this study provides evidence that tryptophan metabolism—the biochemical basis of serotonin production—may be abnormal and heterogeneous in this population. Identifying subgroups with different serotonin biosynthetic profiles could help explain symptom variability and guide personalized treatment approaches, particularly for pharmacological interventions targeting serotonin pathways.
Observed Findings
What the study reports it measured.
- Free tryptophan/competing amino acid ratio was 43% higher in CFS patients compared to controls
- Free serum tryptophan concentration was 48% higher in CFS patients
- Total serum tryptophan concentration was 19% higher in CFS patients
- Competing amino acid concentrations were not significantly different between groups overall but were significantly lower in female CFS patients compared to male CFS patients
- Two provisional subgroups of CFS patients were identified: one with normal serotonin-biosynthetic status and one with elevated status
Inferred Conclusions
What the authors interpret from those results.
- Tryptophan availability to the brain is elevated in CFS patients, potentially increasing serotonin biosynthetic capacity
- CFS patients show heterogeneous serotonin-biosynthetic status, suggesting distinct biochemical subphenotypes that may require different therapeutic approaches
- Gender differences in competing amino acid levels in CFS patients may influence tryptophan metabolism differently between males and females
- Abnormal tryptophan disposition in CFS may have implications for serotonergic pharmacotherapy
Remaining Questions
- Does the elevated tryptophan availability translate to increased brain serotonin synthesis or functional dysregulation, and does it correlate with specific symptom profiles?
- Are the identified subgroups (normal versus elevated serotonin status) stable over time and do they predict treatment response to serotonergic medications?
- What mechanisms drive the elevation in free and total tryptophan in CFS patients—altered hepatic metabolism, increased protein catabolism, or other factors?
- Do gender differences in competing amino acid levels explain differential serotonin dysregulation between male and female CFS patients?
What This Study Does Not Prove
This study does not prove that abnormal tryptophan levels cause ME/CFS symptoms or that they are the primary driver of fatigue and dysfunction. The cross-sectional design establishes association only, not causation. The study also does not demonstrate whether elevated brain tryptophan availability translates to functional serotonin dysregulation or clinical benefit from serotonin-targeting drugs.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Badawy, Abdulla A-B, Morgan, Christopher J, Llewelyn, Meirion B, Albuquerque, Selwyn R J, & Farmer, Anne (2005). Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome.. Journal of psychopharmacology (Oxford, England). https://doi.org/10.1177/0269881105053293
BibTeX
@article{mecfsatlas-badawy-2005-heterogeneity-serum,
author = {Badawy, Abdulla A-B and Morgan, Christopher J and Llewelyn, Meirion B and Albuquerque, Selwyn R J and Farmer, Anne},
title = {Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome.},
journal = {Journal of psychopharmacology (Oxford, England)},
year = {2005},
doi = {10.1177/0269881105053293},
note = {PubMed: 15982993},
url = {https://www.mecfsatlas.com/evidence/badawy-2005-heterogeneity-serum},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-13. https://www.mecfsatlas.com/evidence/badawy-2005-heterogeneity-serum
Contribute
Private, reviewed by a human. Not a public comment thread.